Improvement of the trivalent inactivated flu vaccine using papmv nanoparticles

PLoS ONE

Volumn 6, Issue 6, 2011, Pages

  Savard, Christian ^a   Guérin, Annie ^a   Drouin, Karine ^a   Bolduc, Marilène ^a   Laliberté Gagné, Marie Eve ^a   Dumas, Marie Christine ^a   Majeau, Nathalie ^a   Leclerc, Denis ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

COAT PROTEIN; FLUVIRAL; GAMMA INTERFERON; HEMAGGLUTININ; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; MATRIX PROTEIN; NANOPARTICLE; UNCLASSIFIED DRUG; H1N1 VIRUS HEMAGGLUTININ; INACTIVATED VACCINE; INFLUENZA VIRUS HEMAGGLUTININ;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FERRET; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOGENICITY; LYMPH NODE; MALE; MOSAIC VIRUS; MOUSE; NONHUMAN; PAPAYA VIRUS; POLYACRYLAMIDE GEL ELECTROPHORESIS; SEASONAL INFLUENZA; T LYMPHOCYTE; TH1 CELL; TH2 CELL; VACCINE PRODUCTION; VIRUS STRAIN; AMINO ACID SEQUENCE; ANIMAL; CHEMISTRY; HUMAN; IMMUNOLOGY; INFLUENZA VIRUS A H1N1; METABOLISM; MOLECULAR GENETICS; PAPAYA; SEASON; SECRETION; TRANSPORT AT THE CELLULAR LEVEL; VIROLOGY;

ANIMALIA; FLU VACCINE; MUS; MUSTELA; PAPAYA MOSAIC VIRUS;

AMINO ACID SEQUENCE; ANIMALS; BIOLOGICAL TRANSPORT; CARICA; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; IMMUNITY, HUMORAL; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INTERFERON-GAMMA; LYMPH NODES; MALE; MICE; MOLECULAR SEQUENCE DATA; MOSAIC VIRUSES; NANOPARTICLES; SEASONS; T-LYMPHOCYTES; VACCINES, INACTIVATED;

EID: 79959636703     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0021522     Document Type: Article

References (50)

1. Nichol KL, (2008) Efficacy and effectiveness of influenza vaccination. Vaccine 26: D17-22.
2. Rimmelzwaan GF, McElhaney JE, (2008) Correlates of protection: novel generations of influenza vaccines. Vaccine 26: D41-44.
3. Ada GL, Jones PD, (1986) The immune response to influenza infection. Curr Top Microbiol Immunol 128: 1-54.
4. Couch RB, Kasel JA, (1983) Immunity to influenza in man. Annu Rev Microbiol 37: 529-549.
5. Gorman OT, Bean WJ, Webster RG, (1992) Evolutionary processes in influenza viruses: divergence, rapid evolution, and stasis. Curr Top Microbiol Immunol 176: 75-97.
6. Zucotti GV, Fabianno V, (2010) Strategies for preventing influenza: future perspectives in influenza vaccine technology. Expert Opin Biol Ther 11: 1-4.
7. Greenbaum JA, Kotturi MF, Kim Y, Oseroff C, Vaughan K, et al. (2009) Pre-existing immunity against swine-origin H1N1 influenza viruses in the general human population. Proc Natl Acad Sci USA 106: 20365-20370.
8. Kreijtz JHCM, de Mutsert G, van Baalen CA, Fouchier RAM, Osterhaus ADME, et al. (2008) Cross-recognition of avian H5N1 influenza virus by human cytotoxic T-lymphocyte populations directed to human influenza A virus. J Virol 82: 5161-5166.
9. Lee LY, Ha do LA, Simmons C, de Jong MD, Chau NV, et al. (2008) Memory T cells established by seasonal human influenza A infection cross-react with avian influenza A (H5N1) in healthy individuals. J Clin Invest 118: 3478-3490.
10. Rimmelzwaan GF, Osterhaus AD, (1995) Cytotoxic T lymphocyte memory: role in cross-protective immunity against influenza? Vaccine 13: 703-705.
11. Thomas PG, Keating R, Hulse-Post DJ, Doherty PC, (2006) Cell-mediated protection in influenza infection. Emerg Infect Dis 12: 48-54.
12. Tumpey TM, Renshaw M, Clements JD, Katz JM, (2001) Mucosal delivery of inactivated influenza vaccine induces B-cell-dependent heterosubtypic cross-protection against lethal influenza A H5N1 virus infection. J Virol 75: 5141-5150.
13. Grebe KM, Yewdell JW, Bennink JR, (2008) Heterosubtypic immunity to influenza A virus: where do we stand? Microbes Infect 10: 1024-1029.
14. Aguilar JC, Rodriguez EG, (2007) Vaccine adjuvants revisited. Vaccine 25: 3752-3762.
15. Tremblay MH, Majeau N, Gagné ME, Lecours K, Morin H, et al. (2006) Effect of mutations K97A and E128A on RNA binding and self assembly of papaya mosaic potexvirus coat protein. FEBS J 273: 14-25.
16. Denis J, Majeau N, Acosta-Ramirez E, Savard C, Bédard MC, et al. (2007) Immunogenicity of papaya mosaic virus-like particles fused to a hepatitis C virus epitope: evidence for the critical function of multimerization. Virology 363: 59-68.
17. Denis J, Acosta-Ramirez E, Zhao Y, Hamelin ME, Koukavica I, et al. (2008) Development of a universal influenza A vaccine based on the M2e peptide fused to the papaya mosaic virus (PapMV) vaccine platform. Vaccine 26: 3395-3403.
18. Leclerc D, Beauseigle D, Denis J, Morin H, Paré C, et al. (2007) Proteasome-independent major histocompatibility complex class I cross-presentation mediated by papaya mosaic virus-like particles leads to expansion of specific human T cells. J Virol 81: 1319-1326.
19. Lacasse P, Denis J, Lapointe R, Leclerc D, Lamarre A, (2008) A. Novel plant virus-based vaccine induces protective cytotoxic T-lymphocyte-mediated antiviral immunity through dendritic cell maturation. J Virol 82: 785-794.
20. Sui J, Hwang WC, Perez S, Wei G, Aird D, et al. (2009) Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol 16: 265-273.
21. Atmar RL, Keitel WA, (2009) Adjuvants for pandemic influenza vaccines. Curr Top Microbiol Immunol 333: 323-344.
22. Coutelier JP, van der Logt JT, Heessen FW, Warnier G, Van Snick J, (1987) IgG2a restriction of murine antibodies elicited by viral infections. J Exp Med 165: 64-69.
23. Hocart MJ, Mackenzie JS, Stewart GA, (1989) The immunoglobulin G subclass responses of mice to influenza A virus: the effect of mouse strain, and the neutralizing abilities of individual protein A-purified subclass antibodies. J Gen Virol 70: 2439-2448.
24. Beebe DP, Schreiber RD, Cooper NR, (1983) Neutralization of influenza virus by normal human sera: mechanisms involving antibody and complement. J Immunol 130: 1317-1322.
25. Feng JQ, Mozdzanowska K, Gerhard W, (2002) Complement component C1q enhances the biological activity of influenza virus hemagglutinin-specific antibodies depending on their fine antigen specificity and heavy-chain isotype. J Virol 76: 1369-1378.
26. Huber VC, McKeon RM, Brackin MN, Miller LA, Keating R, et al. (2006) Distinct contributions of vaccine-induced immunoglobulin G1 (IgG1) and IgG2a antibodies to protective immunity against influenza. Clin Vaccine Immunol 13: 981-990.
27. Jegerlehner A, Schmitz N, Storni T, Bachmann MF, (2004) A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. J Immunol 172: 5598-5605.
28. Bungener L, Geeradts F, ter Veer W, Medema J, Wilschut J, et al. (2008) Alum boosts TH2-type antibody responses to whole-inactivated virus influenza vaccine in mice but does not confer superior protection. Vaccine 26: 2350-2359.
29. Khurana S, Chearwae W, Castellino F, Mannischewitz J, King LR, et al. (2009) Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus. Sci Transl Med 2: 15ra15.
30. Guillon C, Mayol K, Terrat C, Compagnon C, Primard C, et al. (2007) Formulation of HIV-1 Tat and p24 antigens by PLA nanoparticles or MF59 impacts the breadth, but not the magnitude, of serum and faecal antibody responses in rabbits. Vaccine 25: 7491-7501.
31. Chen GL, Subbarao K, (2009) Attacking the flu: neutralizing antibodies may lead to 'universal' vaccine. Nat Med 15: 1251-1252.
32. Ekiert DC, Bhabha G, Elsliger MA, Friesen RH, Jongeneeien M, et al. (2009) Antibody recognition of a highly conserved influenza virus epitope. Science 324: 246-251.
33. Gerhard W, Mozdzanowska K, Furchner M, Washko G, Maiese K, (1997) Role of the B-cell response in recovery of mice from primary influenza virus infection. Immunol Rev 159: 95-103.
34. Mozdzanowska K, Maiese K, Furchner M, Gerhard W, (1999) Treatment of influenza virus-infected SCID mice with nonneutralizing antibodies specific for the transmembrane proteins matrix 2 and neuraminidase reduces the pulmonary virus titer but fails to clear the infection. Virology 254: 138-146.
35. Gorman OT, Bean WJ, Kawaoka Y, Webster RG, (1990) Evolution of the nucleoprotein gene of influenza A virus. J Virol 64: 1487-1497.
36. Ito T, Gorman TO, Kawaoka Y, Bean WJ, Webster RJ, (1991) Evolutionary analysis of the influenza A virus M gene with comparison of the M1 and M2 proteins. J Virol 65: 5491-5498.
37. Carragher DM, Kaminski DA, Moquin A, Hartson L, Randall TD, (2008) A novel role for non-neutralizing antibodies against nucleoprotein in facilitating resistance to influenza virus. J Immunol 181: 4168-4176.
38. Nguyen HH, van Ginkel FW, Vu HL, McGhee JR, Mestecky J, (2001) Heterosubtypic immunity to influenza A virus infection requires B cells but not CD8+ cytotoxic T lymphocytes. J Infect Dis 183: 368-376.
39. Rangel-Moreno J, Carragher DM, Misra RS, Kusser K, Hartson L, et al. (2008) B cells promote resistance to heterosubtypic strains of influenza via multiple mechanisms. J Immunol 180: 454-463.
40. Sambhara S, Kurichh A, Miranda R, Tumpey T, Rowe T, et al. (2001) Heterosubtypic immunity against human influenza A viruses, including recently emerged avian H5 and H9 viruses, induced by FLU-ISCOM vaccine in mice requires both cytotoxic T-lymphocyte and macrophage function. Cell Immunol 211: L143-153.
41. Liang S, Mozdzanowska K, Palladino G, Gerhard W, (1994) Heterosubtypic immunity to influenza type A virus in mice. Effector mechanisms and their longevity. J Immunol 152: 1653-1661.
42. Yap KL, Ada GL, (1978) The recovery of mice from influenza virus infection: adoptive transfer of immunity with immune T lymphocytes. Scand J Immunol 7: 389-397.
43. O'Hagan DT, De Gregorio E, (2009) The path to a successful vaccine adjuvant-'the long and winding road'. Drug Discov Today 14: 541-551.
44. Wieseler-Frank J, Maier SF, Watkins LR, (2004) Glial activation and pathological pain. Neurochem Int 45: 389-395.
45. Xu JT, Xin WJ, Zang Y, Wu CY, Liu XG, (2006) The role of tumor necrosis factor-alpha in the neuropathic pain induced by Lumbar 5 ventral root transection in rat. Pain 123: 306-321.
46. Zhou Z, Peng X, Hagshenas J, Insolera R, Fink DJ, et al. (2010) A novel cell-cell signaling by microglial transmembrane TNFalpha with implications for neuropathic pain. Pain 151: 296-306.
47. Donnelly JJ, Friedman A, Martinez D, Montgomery DL, Shiver JW, et al. (1995) Preclinical efficacy of a prototype DNA vaccine: enhanced protection against antigenic drift in influenza virus. Nat Med 1: 583-587.
48. Kodihalli S, Kobasa DL, Webster RG, (2000) Strategies for inducing protection against avian influenza A virus subtypes with DNA vaccines. Vaccine 18: 2592-2599.
49. Xie H, Liu T, Chen H, Huang X, Ye Z, (2007) Evaluating the vaccine potential of an influenza A viral hemagglutinin and matrix double insertion DNA plasmid. Vaccine 25: 7649-7655.
50. Tao P, Luo M, Pan R, Ling D, Zhou S, et al. (2009) Enhanced protective immunity against H5N1 influenza virus challenge by vaccination with DNA expressing a chimeric hemagglutinin in combination with an MHC class I-restricted epitope of nucleoprotein in mice. Antiviral Res 81: 253-260.